Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID

Withdrawn before enrolling

Conditions studied: COVID-19

In brief

AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID.

Key facts

Study ID

NCT06427512

Run by

Columbia University

People needed

0

Starts

2022-03-01

Expected to finish

2025-03-01

Last updated by the study team

2024-05-24

Who can join

Age: 19 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18, < 75 yrs
• History of lab-confirmed COVID
• Symptomatic at >12 wks post-acute COVID (cases)
• Recovered by 8wks post-acute COVID (controls)

You may not qualify if…

• Any history of critical illness
• Chronic kidney disease, Stage >4
• Pre-COVID: HFrEF, CABG, arrhythmia; pulmonary hypertension, pulmonary embolus, interstitial lung disease (ILD), O2 dependence; dementia, stroke, autonomic dysfunction; coagulopathy
• Post-COVID: ILD, O2 dependence

Where it is running

• CUIMC — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.